Results 201 to 210 of about 18,044 (238)
Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis. [PDF]
Psoriasis (Auckl)Gisondi P +3 more
europepmc +1 more source
Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.
JAMA Netw OpenRiegler JS, Kesselheim AS, Rome BN.
europepmc +1 more source
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers [PDF]
ESMO Open, 2016 Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial ...
Josep Tabernero Caturla +2 more
exaly +7 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
International Journal of Nutrition, Pharmacology, Neurological Diseases, 2021
Biologics are medicines primarily derived from living systems and produced through recombinant DNA (rDNA) and monoclonal technologies. Generic version of biologics with improved efficacy and safety is called biosimilar. Patent and copyright expiration of biological products permits the entry of biosimilars.
Saravanan Bhojaraj +10 more
openaire +2 more sources
Biologics are medicines primarily derived from living systems and produced through recombinant DNA (rDNA) and monoclonal technologies. Generic version of biologics with improved efficacy and safety is called biosimilar. Patent and copyright expiration of biological products permits the entry of biosimilars.
Saravanan Bhojaraj +10 more
openaire +2 more sources
European Journal of Hospital Pharmacy, 2019
Biological medicines have become indispensable in the treatment of patients with serious diseases such as cancer and inflammatory diseases. Biosimilars are medicines which are developed to be similar to existing biological medicines (the 'reference product'). For the European market, they are approved by the European Medicines Agency.
András Süle +4 more
openaire +2 more sources
Biological medicines have become indispensable in the treatment of patients with serious diseases such as cancer and inflammatory diseases. Biosimilars are medicines which are developed to be similar to existing biological medicines (the 'reference product'). For the European market, they are approved by the European Medicines Agency.
András Süle +4 more
openaire +2 more sources